- Trials with a EudraCT protocol (65)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
65 result(s) found for: Gastrointestinal Stromal Tumor (GIST).
Displaying page 2 of 4.
EudraCT Number: 2008-002396-28 | Sponsor Protocol Number: IPI-504-06 | Start Date*: 2009-02-18 | |||||||||||
Sponsor Name:Infinity Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients with Metastatic and/or Unresectable Gastrointestinal Stromal Tu... | |||||||||||||
Medical condition: Metastatic and/or unresectable gastro-intestinal stromal tumors in patients following failure of treatment with at least imatinib and sunitinib. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) ES (Completed) SE (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) BE (Completed) FR (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001860-27 | Sponsor Protocol Number: A6181036 | Start Date*: 2007-09-12 | |||||||||||
Sponsor Name:Pfizer Limited | |||||||||||||
Full Title: A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATE | |||||||||||||
Medical condition: Patients with Gastrointestinal Stromal Tumor who are Refractory to Standard Therapy and May Derive Benefit for Treatment with SU011248 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SK (Completed) HU (Completed) FI (Completed) DK (Completed) AT (Prematurely Ended) SE (Completed) ES (Prematurely Ended) GR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003497-14 | Sponsor Protocol Number: BLU-285-1303 | Start Date*: 2018-04-23 | ||||||||||||||||
Sponsor Name:Blueprint Medicines Corporation | ||||||||||||||||||
Full Title: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) | ||||||||||||||||||
Medical condition: Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) SE (Completed) HU (Completed) DE (Completed) NL (Completed) AT (Completed) ES (Completed) BE (Completed) CZ (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-002008-33 | Sponsor Protocol Number: A6181196 | Start Date*: 2012-02-21 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR | |||||||||||||
Medical condition: Pediatric Gastro Intestinal Stromal Tumor (GIST) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Completed) Outside EU/EEA CZ (Completed) PT (Completed) IT (Completed) GB (Completed) PL (Completed) AT (Completed) DE (Completed) FR (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020305-32 | Sponsor Protocol Number: CRAD001CIT27T | Start Date*: 2010-08-06 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
Full Title: A phase II, open label study to evaluate the activity and safety of Everolimus in association to Imatinib in PDGFRA-D842V unresectable or metastatic gastrointestinal stromal tumours (GISTs)as... | |||||||||||||
Medical condition: patients with unresectable and/or metastatic gastrointestinal stromal tumours with exon 18 PDGFRA mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000287-34 | Sponsor Protocol Number: ARO-012 | Start Date*: 2017-05-30 | |||||||||||
Sponsor Name:Arog Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene. | |||||||||||||
Medical condition: Advanced or metastatic gastrointestinal stromal tumor (GIST) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005751-21 | Sponsor Protocol Number: BLU-285-1408 | Start Date*: 2021-04-16 | |||||||||||||||||||||
Sponsor Name:Blueprint Medicines | |||||||||||||||||||||||
Full Title: Open-Label Extension Study to Evaluate the Safety of Long-Term Treatment with Avapritinib for Patients Previously Involved in an Avapritinib Study | |||||||||||||||||||||||
Medical condition: Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003119-77 | Sponsor Protocol Number: NL67828.058.18 | Start Date*: 2020-02-24 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: Near-infrared fluorescence imaging with IndoCyanine Green for the intraoperative identification of Gastrointestinal stromal cell tumours: a pilot study | ||
Medical condition: GIST Gastrointestinal stromal cell tumour | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001093-11 | Sponsor Protocol Number: A6181030 | Start Date*: 2004-12-24 | |||||||||||
Sponsor Name:Pfizer Global Research and Development | |||||||||||||
Full Title: A Treatment Protocol for Patients Continuing from a Prior SU011248 Protocol | |||||||||||||
Medical condition: This is an open-label treatment protocol for patients who have participated in other SU011248 protocols to completion and are believed to have the potential to derive clinical benefit from SU011248... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Prematurely Ended) NL (Completed) SE (Completed) GR (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000358-11 | Sponsor Protocol Number: CAMN107DDE06 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: An open-label, multi-center, single-arm study to evaluate the efficacy of nilotinib in adult patients with metastatic or unresectable gastrointestinal stromal tumors in first line treatment | |||||||||||||
Medical condition: metastatic or unresectable gastrointestinal stromal tumor | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) FI (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004758-34 | Sponsor Protocol Number: CAMN107G2301 | Start Date*: 2009-03-13 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tu... | |||||||||||||
Medical condition: adult patients with histologically confirmed unresectable or metastatic GIST, either who have not received any prior anti-neoplastic therapy or, who experienced recurrence of GIST > 6 months after ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Completed) SK (Completed) CZ (Completed) SE (Completed) HU (Completed) NL (Completed) DE (Completed) FR (Completed) IT (Completed) GB (Completed) DK (Prematurely Ended) GR (Prematurely Ended) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004309-24 | Sponsor Protocol Number: A6181112 | Start Date*: 2007-05-02 | |||||||||||
Sponsor Name:Pfizer Inc., East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE IIIB, RANDOMIZED, ACTIVE CONTROLLED OPEN-LABEL STUDY OF SUNITINIB (SUTENT®) 37.5 MG DAILY VS IMATINIB MESYLATE 800 MG DAILY IN THE TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS... | |||||||||||||
Medical condition: TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) ES (Completed) FR (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000973-40 | Sponsor Protocol Number: AB04030 | Start Date*: 2008-12-18 | |||||||||||
Sponsor Name:AB SCIENCE | |||||||||||||
Full Title: A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in... | |||||||||||||
Medical condition: gastro-intestinal stromal tumour | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) HU (Prematurely Ended) DE (Prohibited by CA) AT (Ongoing) BE (Prematurely Ended) ES (Prematurely Ended) NL (Temporarily Halted) GB (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004162-34 | Sponsor Protocol Number: AB12004 | Start Date*: 2015-01-02 | |||||||||||
Sponsor Name:AB Science | |||||||||||||
Full Title: A prospective, multicenter, randomized, double-blind, placebo-controlled, two-parallel groups, phase III clinical trial to compare the efficacy and safety of masitinib to placebo in patients with l... | |||||||||||||
Medical condition: stromal gastrointestinal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002267-11 | Sponsor Protocol Number: CAMN107A2201 | Start Date*: 2006-11-10 |
Sponsor Name:Novartis Pharma Services | ||
Full Title: A randomized, open-label,multi-center study to evaluate the efficacy of nilotinib versus imatinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and resistant/intolera... | ||
Medical condition: Gastrointestinal stromal tumors (GIST) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) CZ (Completed) BE (Completed) FR (Completed) IT (Completed) DE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-001928-12 | Sponsor Protocol Number: 17/2007/U/Sper | Start Date*: 2007-04-23 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: Contrast enhanced ultrasonography effectiveness in early evaluating of the response to the Sunitinib in the patients with advanced GIST. A pilot study | |||||||||||||
Medical condition: Gastrointestinal stromal tumor (GIST) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002544-27 | Sponsor Protocol Number: CSTI571BDE78T | Start Date*: 2011-10-18 |
Sponsor Name:Technische Universitaet Muenchen Fakultaet fuer Medizin | ||
Full Title: Prospective, explorative trial for the detection of circulating cell-free tumor DNA in the plasma of patients with gastrointestinal stromal tumors (GIST) harboring activating mutations of CKIT or P... | ||
Medical condition: Patients with gastrointestinal stromal tumor (GIST) harboring activating mutations of CKIT or PDGFRA pre/post surgery or pre/under treatment with a Tyrokinase Inhibitors or progressive disease irre... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000898-39 | Sponsor Protocol Number: SSGXXII | Start Date*: 2014-12-19 |
Sponsor Name:Scandinavian Sarcoma Group | ||
Full Title: Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study. | ||
Medical condition: gastrointestinal stromal tumor (GIST) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003998-96 | Sponsor Protocol Number: AXAGIST | Start Date*: 2019-04-03 | |||||||||||
Sponsor Name:Centrum Onkologii – Instytut im. Marii Skłodowskiej - Curie | |||||||||||||
Full Title: A Phase II, single arm Study of avelumab In combination with Axitinib in Patients With unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy - AXAGIST | |||||||||||||
Medical condition: GIST - unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001803-35 | Sponsor Protocol Number: DCC-2618-03-002 | Start Date*: 2019-04-01 | |||||||||||
Sponsor Name:Deciphera Pharmaceuticals, LLC | |||||||||||||
Full Title: A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib | |||||||||||||
Medical condition: Patients with Advanced Gastrointestinal Stromal Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) CZ (Completed) NO (Trial now transitioned) ES (Ongoing) SE (Completed) BE (Completed) NL (Trial now transitioned) HU (Completed) PL (Completed) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
